Table 1.
Comparison of baseline characteristics and cycle related factors between the sildenafil, sildenafil + placebo, and placebo groups prior to intervention
| Variable | Sildenafil n=22 | Sildenafil+placebo n=22 | Placebo n=22 | P value | |
|---|---|---|---|---|---|
| Age (Y) | 33.2 ± 4.6 | 31.7 ± 4.8 | 32.8 ± 4.6 | 0.568 | |
| BMI (kg/m2) | 24.7 ± 3.7 | 26.2 ± 3.6 | 25.2 ± 2.9 | 0.379 | |
| Infertility duration | 8.8 ± 4.9 | 10.5 ± 5.1 | 8 ± 4.1 | 0.220 | |
| Infertility type | |||||
| Primary | 19 (86.4) | 20 (90.9) | 17 (77.3) | ||
| Secondary | 3 (13.6) | 2 (9.1) | 5 (22.7) | 0.438 | |
| Infertility reason | |||||
| Tubal factor | 1 (4.5) | 1 (4.5) | 1 (4.5) | ||
| Male factor | 14 (63.6) | 11 (50) | 11 (50) | ||
| Endometriosis | 0 (0) | 0 (0) | 1 (4.5) | 0.910 | |
| Unexplained | 1 (4.5) | 2 (9.1) | 1 (4.5) | ||
| Two or more | 6 (27.3) | 8 (36.4) | 8 (36.4) | ||
| Endometrial pattern | |||||
| Normal | 18 (81.8) | 18 (81.8) | 19 (86.4) | ||
| Heterogenic | 2 (9.1) | 3 (13.6) | 3 (13.6) | 0.683 | |
| Ecogene | 2 (9.1) | 1 (4.5) | 0 | ||
| Uterine artery PI | |||||
| Right | 2.4 ± 0.7 | 2.5 ± 0.7 | 2.9 ± 0.9 | 0.134 | |
| Left | 2.5 ± 0.8 | 2.7± 0.9 | 2.9 ± 1 | 0.440 | |
| Uterine artery RI | |||||
| Right | 80.1 ± 19.3 | 69.7 ± 32.7 | 74.2 ± 31.2 | 0.474 | |
| Left | 76.5 ± 25.2 | 66.4 ± 35.7 | 74 ± 31 | 0.527 | |
| Endometrial thickness | 8.0 ± 2.4 | 8.9 ± 2.0 | 7.6 ± 2.1 | 0.146 | |
| Type of gonadotropins | |||||
| FSH (75 IU/mL) | 5 (22.7) | 8 (36.4) | 3 (13.6) | 0.209 | |
| FSH+LH (75 IU/mL) | 17 (77.3) | 14 (63.6) | 19 (86.4) | ||
| Ovulation duration | 9.9 ± 2.1 | 10.3 ± 2.2 | 9.1 ± 1.3 | 0.100 | |
| Ampoules (n) | 9.1 ± 12.2 | 9.6 ± 14.6 | 7.8 ± 8.5 | 0.871 | |
| Oocytes (n) | 11.5 ± 5.6 | 11.6 ± 6.7 | 8.1 ± 5.5 | 0.098 | |
| MII (n) | 9.3 ± 5.1 | 9.4 ± 5.8 | 6.3 ± 4.1 | 0.079 | |
BMI; Body mass index, PI; Pulsatility index, FSH; Follicle stimulating hormone, LH; Luteinizing hormone, RI; Resistance index, and MII; Mature metaphase II.